Xeris Anticipates 2025 Revenue of $292 Million, Exceeding Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Source: Newsfilter
- Revenue Growth: Xeris anticipates total revenue of $292 million for 2025, exceeding the guidance range of $285-$290 million and reflecting a 44% increase from the previous year, indicating strong market demand and product performance.
- Product Performance: Recorlev® achieved net revenue of $45 million in Q4 2025 and $139 million for the full year, demonstrating increasing market acceptance in treating endogenous Cushing's syndrome.
- Patient Base Expansion: By the end of 2025, approximately 700 patients were on Recorlev® therapy, while Gvoke® saw revenue growth of over 13% year-over-year, showcasing the company's success in patient treatment and market penetration.
- Financial Stability: Xeris delivered positive adjusted EBITDA in every quarter, reinforcing the company's financial foundation and positioning it for sustained growth in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XERS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XERS
Wall Street analysts forecast XERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XERS is 11.00 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.240
Low
8.00
Averages
11.00
High
18.00
Current: 7.240
Low
8.00
Averages
11.00
High
18.00
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analyst Target Prices Indicate Potential for Pharmaceuticals ETF
- ETF Upside Potential: The iShares U.S. Pharmaceuticals ETF (IHE) has an implied analyst target price of $96.28 per unit, while trading at $86.15, indicating an 11.76% upside, reflecting market optimism about the ETF's future performance.
- MBX Stock Analysis: MBX BIOSCIENCES INC (MBX) trades at $35.83, with an analyst target price of $60.55, suggesting a potential upside of 69.01%, showcasing investor confidence in its future prospects.
- CRNX Stock Outlook: Crinetics Pharmaceuticals Inc (CRNX) has a current price of $51.32 and an analyst target of $83.46, indicating a 62.63% upside, reflecting positive market sentiment regarding its product and R&D advancements.
- XERS Investment Opportunity: Xeris Biopharma Holdings Inc (XERS) is priced at $7.14, with an analyst target of $11.14, showing a 56.05% upside, indicating analysts' optimism about its growth potential.
Continue Reading
Xeris Anticipates 2025 Revenue of $292 Million, Exceeding Guidance
- Revenue Growth: Xeris anticipates total revenue of $292 million for 2025, exceeding the guidance range of $285-$290 million and reflecting a 44% increase from the previous year, indicating strong market demand and product performance.
- Product Performance: Recorlev® achieved net revenue of $45 million in Q4 2025 and $139 million for the full year, demonstrating increasing market acceptance in treating endogenous Cushing's syndrome.
- Patient Base Expansion: By the end of 2025, approximately 700 patients were on Recorlev® therapy, while Gvoke® saw revenue growth of over 13% year-over-year, showcasing the company's success in patient treatment and market penetration.
- Financial Stability: Xeris delivered positive adjusted EBITDA in every quarter, reinforcing the company's financial foundation and positioning it for sustained growth in the future.
Continue Reading